It is a common fact among pharmaceutical industry that China is a rapidly maturing market. Vivo Ventures is another company which endeavours to tap into this growing market as it dedicates nearly half of its latest $375 million fund to Chinese drugmakers.
The U.S. venture outfit has set up a seventh fund specifically with the aim of targetting Chinese drug companies in commercial stages. 55% of the new fund will also be injected into U.S. makers and developers of therapeutics by Vivo as it
seeks the best possible solution for the more than $1 billion fund under its management.
When interviewed, Vivo Managing Partner James Zhao said, “We hope to create synergy between U.S. and Chinese companies, and maximize shareholder value,” He added that cooperation is better than competition and alliance is better than isolation, a strategy commonly adopted by many other pharmaceutical companies as well in terms of their expansion and growth.
China as the world’s second-largest national economy and consumers with money for modern medical treatments offers major growth opportunities to drugmakers from inside the country and overseas. Venture capital firms like Vivo, which already has a dozen China investments, will be one of the few who seek to become a major stakeholder in the growing pharmaceutical industry in China.
Several other similar venture capital companies will be sending their representatives to grace the 5th annual BioPharma Asia Convention with their expertise and knowledge in the field of partnering and investment. Soffinova Ventures, for one, will be sending its Venture Partner, Mr Goro Takeda will be speaking at Pharma Partnering & Investment World Asia on “Recognizing the criteria that VCs look for when investing in small startup companies”. Mr John Diekman, Partner for 5AM Ventures meanwhile will be speaking in the panel discussion “Success strategies in identifying and evaluating investment prospects in Asia” while Managing Partner for Rock Spring Ventures, Mr. A Sinclair Dunlop will be speaking in the panel discussion “Success strategies in identifying and evaluating investment prospects in Asia” and individual topic “Collaboration for success: Managing expectations on both sides of a partnership” Dr Alfred Scheidegger, Founding Partner & Chief Executive Officer for Nextech Invest Ltd. is another member of the panel discussion. He will also be speaking on individual topic “Opportunities and challenges of strategic partnering for life science ventures”
See you in Marina Bay Sands at March this year!